Researchers at SK Bioscience are researching the development of a COVID-19 vaccine.  (provided by SK bioscience)
News
gla_wpadmin  

‘Korea’s first vaccine’… SK vasa’s coronavirus vaccine ‘excellent’ clinical results, up 6%

Researchers at SK Bioscience are researching the development of a COVID-19 vaccine. (provided by SK bioscience)

The COVID-19 vaccine being developed by SK Bioscience has secured excellent phase 3 clinical results. The stock price is rising on the news that it will apply for an official product license to the Ministry of Food and Drug Safety this month.

At 11:25 am on April 25, SK Bioscience is trading at 132,000 won, up 3.53% from the previous trading day. The stock has maintained a good trend throughout the morning, increasing 6.67% during the day to 136,000 won.

On April 25, SK Bioscience announced that its self-developed synthetic antigen-based COVID-19 vaccine candidate ‘GBP510’ showed an excellent immune response compared to the control vaccine in the results of phase 3 clinical trial. GBP510 is a COVID-19 vaccine candidate jointly developed by SK Bioscience and the Institute of Antigen Design (IPD) of the University of Washington University of Pharmacy, with support from the Bill & Melinda Gates Foundation (BMGF) and the Coalition for Epidemic Prevention and Innovation (CEPI). Global pharmaceutical company GSK’s immune enhancing substance ‘AS03’ was applied.

This phase 3 clinical trial was conducted on 4,037 adults over the age of 18 in 16 clinical institutions in Korea, including Korea University Guro Hospital, and 5 overseas countries including Thailand, Vietnam, New Zealand, Ukraine and the Philippines. As a result, superiority was demonstrated in terms of immunogenicity over ‘Vaxzevria’, a control vaccine, when administered twice at an interval of 4 weeks. Boxzebria is a vaccine jointly developed by AstraZeneca, a global pharmaceutical company, and Oxford University, UK.

In particular, GBP510 showed superiority in significantly improving the number of neutralizing antibodies compared to the control vaccine in the analysis of neutralizing antibodies that neutralize COVID-19 infectivity and induce a preventive effect. In addition, the antibody conversion rate, which refers to the proportion of clinical subjects who increased the number of neutralizing antibodies in the body by 4 times or more after GBP510 inoculation, was also significantly higher than that of the control vaccine.

SK Bioscience plans to secure the safety data of GBP510 by the end of this month and apply for an official product license to the Ministry of Food and Drug Safety. If the Ministry of Food and Drug Safety obtains product approval, Korea’s first COVID-19 vaccine will be born, and Korea will become an independent Corona 19 vaccine exporter.

The news that President-elect Yoon Seok-yeol will visit SK Bioscience’s headquarters in Seongnam, Gyeonggi Province on the same day is also believed to have driven the stock price rise. President-elect Yoon is said to be emphasizing Korea’s will to ‘vaccine sovereignty’ by checking the current status of COVID-19 vaccine development and technology. It can be interpreted that the expectation that SK Bioscience is likely to benefit from the next government is reflected in the stock price. President-elect Bae Hyun-jin, spokeswoman for the President-elect, said at a briefing of the Presidential Transition Committee on the same day, “President-elect Yoon will encourage developers who are working on the development with a sense of mission to secure the sovereignty of the COVID-19 vaccine.”

[신은빈 인턴기자]


[ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]

Reference-www.mk.co.kr

Leave A Comment